Dementia presents an escalating public health challenge worldwide. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Neuropsychiatric symptoms (NPS), commonly concomitant with Alzheimer's disease (AD), substantially impair the quality of life and accelerate disease progression, yet reliable biomarkers for early identification of individuals at high NPS risk remain elusive. 4 key findings →
Design: longitudinal study Participants: 509 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
54/100
Eight studies comprising 984 patients met inclusion criteria. 5 key findings →
Design: systematic review Participants: 984 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This narrative review integrates longitudinal cohort studies, neuroimaging and biomarker research, and major clinical trials to examine how depression and cognitive decline interact across the dementia continuum. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Both groups exhibited significant, transient microbiome remodeling at Year 1 (the period of most active weight loss). 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Dementia prevalence was 22%, with 35% undiagnosed. 4 key findings →
Design: prospective cohort Participants: 2,003 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This study aimed to identify lipid species associated with MPH response and explore lipid pathway disruptions in responders versus non-responders. 3 key findings →
Design: randomized controlled trial Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
54/100
AD-MCI and AD-DEM patients showed increased p-tau217 and spectral slowing (higher theta, lower alpha). 4 key findings →
Participants: 128 Evidence: low
Full summary, score breakdown and related studies → Original source
In response to correspondence from Cognivue, Inc. regarding our publication (Jannati et al., 2025), we clarify that our analysis employed a rigorous paired-sample design using the same 930 participants from the Bio-Hermes-001 study for both the Digital Clock and Recall® (DCR) and Cognivue Clarity® assessments. 3 key findings →
Participants: 930 Evidence: low
Full summary, score breakdown and related studies → Original source
Amyloid-related imaging abnormalities (ARIA) are the principal safety concern limiting anti-amyloid therapies for Alzheimer's disease, yet their biology remains unclear. 3 key findings →
Design: case-control Participants: 3 Evidence: preliminary
Full summary, score breakdown and related studies → Original source Free full text
Increased UPF consumption is associated with higher risks of dementia, CIND, and CIND or dementia among US older adults. 4 key findings →
Design: cohort Participants: 5,370 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Epilepsy was associated with higher subsequent recording of dementia and mortality over 2 years. 4 key findings →
Design: cohort study Participants: 1,812 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
53/100
Moreover, there is limited knowledge regarding associations with domain-specific cognitive decline and modifying effects of key individual characteristics. 4 key findings →
Design: cohort study Participants: 2,008 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Late-onset unexplained epilepsy (LOUE) represents a substantial proportion of epilepsies with onset after 50 years and often manifests as temporal lobe epilepsy (LO-TLE). 4 key findings →
Design: cohort study Participants: 18 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
To efficiently implement plasma and cerebrospinal fluid (CSF) biomarkers for staging and prognosis of Alzheimer disease (AD), we must understand their dynamics across disease progression. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Significant interactions between amyloid status and modifiable risk factors were observed for diabetes (adjusted β = -0.206, p = 0.032), high cholesterol (adjusted β = -0.155, p < 0.001), and physical inactivity (adjusted β = -0.161, p = 0.046), indicating combined effects rather than additive effects on cognitive decline among Aβ+ individuals. 5 key findings →
Design: cohort study Participants: 1,707 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Across imputed data sets, a median of 2,777 eligible individuals were included, with a median of 664 receiving a new HA prescription. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Due to rapid population aging, the number of Chileans with dementia is estimated to triple by 2050. 1 key finding →
Design: longitudinal study Participants: 1,778 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Pathophysiologic-constrained ADL provided interpretable, personalized pathologic maps and an AI-derived ADAD score that more closely linked PET pathologic abnormalities with multimodal clinical measures. © RSNA, 2026 3 key findings →
Design: longitudinal study Participants: 7,457 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Both ML short forms showed high internal consistency (α = 0.96 for ML-WHODAS-16 and 0.93 for ML-WHODAS-10) and excellent concurrent validity with the full WHODAS-32 (r = 0.98 for both). 5 key findings →
Design: longitudinal study Participants: 31,952 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
53/100
The best-performing model achieved an area under the curve of 0.86 (95% confidence interval [CI]: 0.84-0.87), with sensitivity of 73.3% (95% CI: 72.3-74.2) and specificity of 87.5% (95% CI: 86.7-88.2). 5 key findings →
Design: case-control study Participants: 8,195 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
P-tau217 demonstrated the most significant inter-group differences, the highest hazard ratio, and best distinguished MCI-Converters from MCI-Nonconverters, with its discriminative performance comparable to that of Aβ-PET measures and multi-plasma biomarker models. 5 key findings →
Design: longitudinal study Participants: 47 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Parkinson's disease (PD) is a neurodegenerative condition that may affect both motor and cognitive function. 1 key finding →
Design: longitudinal study Participants: 115 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Most dementias are preceded by mild cognitive impairment (MCI), a transitional clinical stage characterized by cognitive decline that does not yet significantly interfere with activities of daily living. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Accurate prediction of progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD) is critical for early intervention. 1 key finding →
Design: longitudinal study Participants: 596 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →